Analysts at Barclays initiated coverage on Quest Diagnostics Inc. DGX with a Equalweight rating, according to sources.
The target price for Quest Diagnostics is set to $78.
Quest Diagnostics shares have gained 33.91% over the past 52 weeks, while the S&P 500 index has surged 14.02% in the same period.
Quest Diagnostics' shares fell 1.35% to close at $70.14 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in